The Future of HIV Treatment is Here: Once-a-Month Injections to Replace Daily Oral Medications

A combination of antiretroviral drugs in long-acting nanosuspension formulations achieved adequate blood levels and appeared safe in HIV negative study volunteers, offering the potential for a maintenance or PrEP option that could be taken once monthly, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.

While modern antiretroviral therapy is highly safe and effective, agents that could be administered less frequently would improve convenience for people with HIV. A long-acting option could prove especially attractive for maintenance therapy once viral load is suppressed, or for pre-exposure prophylaxis (PrEP) in HIV negative people.

Click here for more details

New HIV Drugs and Formulations in the Near Future (CROI 2013 Presentation)

All of the presentations in this section were great.

The one on new drugs is contained in the last set of slides (blue slides at 1:22:46)

http://webcasts.retroconference.org/console/player/19437?mediaType=podiumVideo


For individual reports on each drug (Thanks to Natap.org):

NEW HIV DRUGS at CROI

Dolutegravir Treatment Response and Safety by Key Subgroups in Treatment Naive HIV Infected Individuals - (03/16/13)

Dolutegravir (DTG) Versus Raltegravir (RAL) in ART-Experienced, Integrase-Naive Subjects: 24-Week Interim Results From SAILING (ING111762) - (03/06/13)

Dolutegravir Superior to Raltegravir in ART-Experienced Integrase Inhibitor Naive at 24 Weeks - written by Mark Mascolini - (03/06/13)

Distribution and Antiviral Activity in Cerebrospinal Fluid (CSF) of the Integrase Inhibitor, Dolutegravir (DTG): ING116070 Week 16 Results - (03/06/13)

Safety and Antiviral Activity of MK-1439, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), In Treatment-Naïve HIV-Infected Patients - (03/05/13)

Seven-Day Monotherapy With New NNRTI Yields Sharp Viral Load Drop - written by Mark Mascolini - (03/05/13)

Comparative Study of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate, Each with Elvitegravir, Cobicistat, and Emtricitabine, for HIV Treatment - (03/05/13)

New tenofovir prodrug virologically equivalent to TDF--and easier on kidneys and bone - written by Mark Mascolini - (03/05/13)

A Tenofovir Disoproxil Fumarate Intravaginal Ring Completely Protects Against Repeated SHIV Vaginal Challenge in Nonhuman Primates - (03/11/13)

Tenofovir in Intravaginal Ring Protects 6 of 6 Macaques From SHIV Challenge - written by Mark Mascolini - (03/08/13)

Week 24 Primary Analysis of Cenicriviroc vs Efavirenz, in Combination with FTC/TDF, in Treatment-naïve HIV-1 Infected Adults with CCR5-tropic virus - (03/08/13)

CCR5/CCR2 Antagonist Cenicriviroc: 24-Week Data vs Efavirenz in ART-Naive - written by Mark Mascolini - (03/08/13)

PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys - (03/07/13)

Long-Acting Integrase Inhibitor Shields Macaques From Anal Simian HIV - written by Mark Mascolini - (03/04/13)